Thus it appears that, though outgrowth of pre-existing X4-tropic viruses in the quasispecies remains a problem for the therapeutic administration of CCR5 antagonists, de novo mutations conferring altered coreceptor usage may not be the favored pathway for resistance in vitro or in vivo.
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}